- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00092053
Study of Investigational Drug in Osteoporosis (MK-0217-908)
February 1, 2022 updated by: Organon and Co
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Persistence of the Effect of Oral Monthly Ibandronate on Bone Reception in Postmenopausal Women in Osteoporosis
The purpose of this study is to evaluate the efficacy and safety of an investigational drug in postmenopausal women with osteoporosis.
The primary hypothesis of this study is that in postmenopausal women with osteoporosis, oral monthly ibandronate, at doses of 100 mg and 150 mg, does not achieve persistence in reduction of bone resorption throughout the monthly dosing interval, as demonstrated by a larger change in the serum carboxyterminal crosslinked telopeptide of Type I collagen (CTX-I) log-transformed fraction from baseline four weeks post dose compared to one week post dose, during the third month of treatment, in the participants taking ibandronate than in the participants taking placebo.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
203
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria: -postmenopausal for at least 3 years, with osteoporosis at any of the following sites: [BMD > 2.0 standard deviations below young normal mean bone mass for the hip trochanter, PA lumbar spine (L1 to L4), total hip, or femoral neck based on the normative database provided by each individual manufacturer].
- willing to take study-supplied calcium and vitamin D supplement (or equivalent) and to discontinue any non-study calcium supplements for run-in period and the duration of the study. Exclusion Criteria: -pregnant or lactating, or of childbearing potential.
- participated in another therapeutic trial with an investigational compound within 30 days of randomization.
- history of hypersensitivity to any component of ibandronate tablets or has hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
- an abnormality of the esophagus which delays esophageal emptying such as stricture or achalasia.
- unable to stand or sit upright for at least 60 minutes once a month.
- current use of illicit drugs, or history of drug or alcohol abuse within the past five years.
- has any of the following: hypocalcemia; any severe malabsorption syndrome; moderate or severe hypertension which is uncontrolled; new onset angina or myocardial infarction within six months of entry into the study; evidence for impaired renal function; organ transplantation; or other significant end organ diseases (genitourinary, cardiovascular, endocrine, hepatic, psychiatric, renal, hematologic, or pulmonary).
- history of or evidence of metabolic bone disease (other than postmenopausal bone loss).
- clinical fracture in the past year.
- is receiving or has received treatment prior to randomization which might influence bone turnover.
- is receiving or expected to receive during the course of the study any medication (other than study medication) which might alter bone or calcium metabolism, including Vitamin A in excess of 10,000 IU per day or Vitamin D in excess of 5000 IU per day, calcitonin, phenytoin, heparin, or lithium.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Participants will receive 3 placebo tablets once a month, for 3 months, on the first day of each treatment cycle.
|
tablets
|
Experimental: ibandronate 100 mg
Participants will receive 2 ibandronate 50 mg tablets and 1 placebo tablet once a month, for 3 months, on the first day of each treatment cycle.
|
50 mg tablets
|
Experimental: ibandronate 150 mg
Participants will receive 3 ibandronate 50 mg tablets once a month, for 3 months, on the first day of each treatment cycle.
|
50 mg tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in serum levels of CTX-I (log-transformed fraction) from Week 9 to Week 12
Time Frame: Baseline, Week 9, Week 12
|
Baseline, Week 9, Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2004
Primary Completion (Actual)
July 1, 2005
Study Completion (Actual)
July 1, 2005
Study Registration Dates
First Submitted
September 21, 2004
First Submitted That Met QC Criteria
September 23, 2004
First Posted (Estimate)
September 24, 2004
Study Record Updates
Last Update Posted (Actual)
February 2, 2022
Last Update Submitted That Met QC Criteria
February 1, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0217-908
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postmenopausal Osteoporosis
-
AmgenCompletedPostmenopausal Osteoporosis (PMO)Japan
-
Deltanoid PharmaceuticalsCompletedPostmenopausal Osteoporosis, Multiple Sites
-
Riphah International UniversityCompletedPostmenopausal Osteoporosis | Postmenopausal OsteopeniaPakistan
-
Organon and CoCompletedOsteoporosis Postmenopausal
-
AmgenCompletedPostmenopausal OsteoporosisUnited States, Canada, Denmark, Germany, Belgium, Colombia, Czechia, Japan, Mexico, Poland, Switzerland, Hungary, Spain, Australia, Romania, United Kingdom, India, Argentina, Brazil, Dominican Republic, Estonia, Latvia, Lithuania, New...
-
Penn State UniversityCalifornia Dried Plum BoardActive, not recruiting
-
Massachusetts General HospitalNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedPostmenopausal OsteoporosisUnited States
-
Sahlgrenska University Hospital, SwedenBioGaia ABCompletedPostmenopausal OsteoporosisSweden
-
Samsung Bioepis Co., Ltd.CompletedPostmenopausal OsteoporosisPoland
-
Nigde Omer Halisdemir UniversityCompletedPostmenopausal OsteoporosisTurkey
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States